Clinical trial
Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following…
NCT00330018 · Hadassah Medical Organization, Other · Completed
Key facts
| NCT number | NCT00330018 |
|---|---|
| Title | Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT) |
| Official title | An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation |
| Lead sponsor | Hadassah Medical Organization, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bone Marrow Transplantation, Cytomegalovirus |
| Intervention type | Drug |
| Interventions | Valganciclovir, Acyclovir |
| Enrollment | 40 |
| Start date | Feb 1, 2006 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | May 25, 2006 |
| Last update posted | Apr 21, 2015 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: